Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) announced that company management will participate in a fireside chat at the 2025 Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 3:30 p.m. GMT in London.
The event will be available via a live webcast in the company's investor section at www.beamtx.com and the webcast will be archived for 60 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – BEAM
In the Nov 12 session, BEAM declined 2.71%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.5% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the 2025 Jefferies London Healthcare Conference on Wednesday, November 19, 2025, at 3:30 p.m. GMT in London.
The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
